Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Knight Therapeutics (KHTRF)
OTHER OTC:KHTRF
RESEARCH TOOLSreports
Knight Therapeutics (KHTRF) Stock Price & Analysis
31 Followers
KHTRF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.15 - $4.29
Previous Close$3.98
Volume75.00
Average Volume (3M)8.40K
Market Cap
$403.28M
Enterprise Value$340.52M
Total Cash (Recent Filing)C$154.42M
Total Debt (Recent Filing)C$69.09M
Price to Earnings (P/E)-32.4
Beta0.52
Next Earnings
May 09, 2024EPS Estimate
>-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding104,360,736
10 Day Avg. Volume5,668
30 Day Avg. Volume8,397
Standard Deviation0.07
R-Squared0.25
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.50
Price to Sales (P/S)1.25
Price to Cash Flow (P/CF)7.60
P/FCF Ratio6.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.84Price Target Upside22.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Knight Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
88.91% Insiders
1.86% Mutual Funds
0.73% Other Institutional Investors
8.51% Public Companies and
Individual Investors
KHTRF FAQ
What was Knight Therapeutics’s price range in the past 12 months?
Knight Therapeutics lowest stock price was $3.15 and its highest was $4.29 in the past 12 months.
What is Knight Therapeutics’s market cap?
Currently, no data Available
When is Knight Therapeutics’s upcoming earnings report date?
Knight Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 23 days.
How were Knight Therapeutics’s earnings last quarter?
Knight Therapeutics released its earnings results on Mar 21, 2024. The company reported -$0.169 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.16.
Is Knight Therapeutics overvalued?
According to Wall Street analysts Knight Therapeutics’s price is currently Undervalued.
Does Knight Therapeutics pay dividends?
Knight Therapeutics does not currently pay dividends.
What is Knight Therapeutics’s EPS estimate?
Knight Therapeutics’s EPS estimate is >-$0.01.
How many shares outstanding does Knight Therapeutics have?
Knight Therapeutics has 101,170,380 shares outstanding.
What happened to Knight Therapeutics’s price movement after its last earnings report?
Knight Therapeutics reported an EPS of -$0.169 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went down -3.242%.
Which hedge fund is a major shareholder of Knight Therapeutics?
Currently, no hedge funds are holding shares in KHTRF
---
Knight Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.84 (22.84% Upside)
$4.84 (22.84% Upside)
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.56%
12-Months-Change
Fundamentals
Return on Equity
-2.08%
Trailing 12-Months
Asset Growth
-7.89%
Trailing 12-Months
Company Description
Knight Therapeutics
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.
---
KHTRF Earnings Call
Q4 2024
0:00 / 0:00
---
KHTRF Stock 12 Months Forecast
Average Price Target
$4.84
▲(22.84% Upside)
Technical Analysis
Best Analysts Covering KHTRF
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
-4.54%
reiterated a buy rating 27 days ago
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of -4.54% per trade.
---